ABSTRACT
BACKGROUND: Global initiative for asthma (GINA) 2019 recommends adding a long-acting ß2-agonist (LABA) to an inhaled corticosteroid (ICS) as a maintenance controller therapy in patients with inadequately controlled asthma. Indacaterol acetate (IND, a LABA) in combination with mometasone furoate (MF, an ICS) is under development for the treatment of these patients. OBJECTIVE: This phase III QUARTZ was a multicentre, randomised, double-blind, double-dummy and parallel-group study to assess the efficacy and safety of low-dose IND/MF 150/80⯵g once daily (o.d.) versus MF 200⯵g o.d. in adult and adolescent patients with inadequately controlled asthma. METHODS: Eligible patients (nâ¯=â¯802) were randomised (1:1) to receive either low-dose IND/MF 150/80⯵g o.d. via Breezhaler® or MF 200⯵g o.d. via Twisthaler® for 12 weeks. Primary endpoint was trough forced expiratory volume in 1â¯s (FEV1) and key secondary endpoint was Asthma Control Questionnaire (ACQ-7) treatment difference after 12-week treatment. Other secondary endpoints included ACQ-7 responder analysis, morning and evening peak expiratory flow, Asthma Quality of Life Questionnaire total score, rescue medication use, daily symptom score, nighttime awakenings and rate of exacerbations, evaluated over 12-week treatment. Safety was also assessed including serious asthma outcomes. RESULTS: Low-dose IND/MF significantly improved trough FEV1 (least squares mean treatment difference [LSMTD]: 0.182â¯L; pâ¯<â¯0.001) and ACQ-7 (LSMTD: -0.218; pâ¯<â¯0.001) versus MF at Week 12. Improvements in all other secondary endpoints favoured low-dose IND/MF. Safety was comparable. CONCLUSION: These results support the use of low-dose IND/MF 150/80⯵g o.d. as a potential therapy for adult and adolescent patients with inadequately controlled asthma.